彭文苗++++张志敏++胡萌+余丽芳+++章必成+饶智国

    [摘要] 目的 研究胃癌組织中核糖体蛋白L23(RPL23)、鼠双微体2(MDM2)蛋白表达与术后辅助化疗效果及毒副反应之间的关系，对胃癌化疗获益人群进行探索性分析。 方法 回顾性收集胃癌根治术并行术后辅助化疗患者34例，免疫组化检测胃癌组织中RPL23、MDM2表达，统计学分析其与3年无病生存期(DFS)及化疗毒副反应之间的关系。 结果 34例患者中，RPL23、MDM2阳性表达率分别为23.5%、58.8%。RPL23(χ2=9.946，P = 0.002)、MDM2(χ2=12.560，P 0.05)。 结论 RPL23、MDM2在胃癌组织中表达有可能作为患者术后辅助化疗效果及血液毒副反应的预测指标。

    [关键词] 核糖体蛋白L23；鼠双微体2；胃癌；基因；术后辅助化疗；疗效；毒副反应

    [中图分类号] R735.7 [文献标识码] A [文章编号] 1673-7210(2017)04(b)-0083-04

    [Abstract] Objective To investigate the correlation of expression of ribosomal protein L23 (RPL23)， murine double minute 2 (MDM2) in gastric cancer tissue with the curative effect of postoperative adjuvant chemotherapy and adverse reactions， so as to make exploratory analysis for the specific group benefited from chemotherapy of gastric cancer. Methods Thirty-four patients with gastric cancer received radical gastrectomy and postoperative adjuvant chemotherapy were collected retrospectively. The expression of RPL23 and MDM2 in the gastric cancer tissue was detected by immunohistochemistry. The relationship of their expression with 3-year disease-free survival (DFS) and adverse reactions were analyzed statistically. Results Among 34 patients ......